Need for cooperation to ensure a robust global framework for clinical trials stressed at EMEA workshop

As part of its strategy to tighten up the supervision of clinical trials conducted in "third” countries, last week the European Medicines Agency (EMEA) held an international workshop with a broad cross section of stakeholders from around the world to discuss a way forward for a global framework of clinical trials that has at its heart the protection of the rights, safety and wellbeing of patients participating in clinical trials anywhere in the world.

The workshop was part of the consultation process on the Agency’s Reflection Paper on ethical and Good Clinical Practice (GCP) aspects of clinical trials of medicinal products for human use conducted in third countries and submitted in marketing authorization applications to the EMEA.

170 participants from 50 countries